<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00807170</url>
  </required_header>
  <id_info>
    <org_study_id>D4200C00085</org_study_id>
    <secondary_id>EUDRACT Number 2008-005556-24</secondary_id>
    <nct_id>NCT00807170</nct_id>
  </id_info>
  <brief_title>Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases</brief_title>
  <official_title>A Phase I Study of ZD6474 (Vandetanib) Concurrent With Whole Brain Radiotherapy for the Treatment of Brain Metastases in Patients With Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to investigate the maximum tolerated dose of Vandetanib and concurrent WBRT
      in patients with NSCLC and brain metastases. All patients will receive WBRT, 10 fractions of
      3 Gy. Patients will start 7 days prior to start of radiation treatment with Vandetanib. Total
      treatment time with Vandetanib is 3 weeks (21 days). Patients will have the opportunity to
      continue Vandetanib until progression at a dose of 300 mg. This multi-centre study will be
      conducted in a minimum of 9 patients and a maximum of 18 patients at 3 sites.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Very slow recruitment
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the maximum tolerated dose of Vandetanib and concurrent WBRT in patients with NSCLC and brain metastases</measure>
    <time_frame>All evaluable patients (all registered patients who receive at least opne dose of study medication) who have completed week 9 study period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the time to clinical and radiological progression of brain metastases</measure>
    <time_frame>Until disease progression</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Non-small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>ZACTIMA TM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD6474 (Vandetanib)</intervention_name>
    <description>100 mg as a once daily oral dose, 21 days</description>
    <arm_group_label>ZACTIMA TM</arm_group_label>
    <other_name>ZACTIMA TM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole Brain Radiotherapy (WBRT)</intervention_name>
    <arm_group_label>ZACTIMA TM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD6474</intervention_name>
    <description>200 mg as a once daily oral dose, 21 days</description>
    <arm_group_label>ZACTIMA TM</arm_group_label>
    <other_name>ZACTIMA TM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD6474</intervention_name>
    <description>300 mg as a once daily oral dose, 21 days</description>
    <arm_group_label>ZACTIMA TM</arm_group_label>
    <other_name>ZACTIMA TM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients aged above 18 years with histologically or cytologically
             confirmed NSCLC and contrast-enhanced CT scan or Gadolinium-enhanced MRI confirmed
             brain metastases who have a performance status of 0 to 2

          -  No previous radiotherapy, surgery or chemotherapy for brain metastases

          -  Patients should not have any unstable systemic disease

        Exclusion Criteria:

          -  Serious abnormal laboratory values

          -  Evidence of severe or uncontrolled systemic disease or any concurrent condition which
             in the Investigator's opinion makes it undesirable for the patient to participate in
             the trial or which would jeopardize compliance with the protocol

          -  Clinically significant cardiovascular event (e.g. myocardial infarction, superior vena
             cava syndrome (SVC), New York Heart Association (NYHA) classification of heart disease
             &gt;2 within 3 months before entry; or presence of cardiac disease that, in the

          -  Previous randomization of treatment in the present study and/ or current participation
             in another clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2008</study_first_submitted>
  <study_first_submitted_qc>December 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2008</study_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer (NSCLC)</keyword>
  <keyword>Whole Brain Radiotherapy</keyword>
  <keyword>metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

